GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Haleon PLC (XTER:H6D0) » Definitions » Short-Term Debt

Haleon (XTER:H6D0) Short-Term Debt : €1,735 Mil (As of Dec. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Haleon Short-Term Debt?

Haleon's Short-Term Debt for the quarter that ended in Dec. 2024 was €1,735 Mil.

Haleon's quarterly Short-Term Debt declined from Jun. 2024 (€1,661 Mil) to Sep. 2024 (€0 Mil) but then increased from Sep. 2024 (€0 Mil) to Dec. 2024 (€1,735 Mil).

Haleon's annual Short-Term Debt increased from Dec. 2022 (€452 Mil) to Dec. 2023 (€706 Mil) and increased from Dec. 2023 (€706 Mil) to Dec. 2024 (€1,735 Mil).

Haleon Short-Term Debt Historical Data

The historical data trend for Haleon's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Haleon Short-Term Debt Chart

Haleon Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Short-Term Debt
Get a 7-Day Free Trial 384.48 1,028.58 451.88 705.74 1,734.94

Haleon Quarterly Data
Dec19 Dec20 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 705.74 - 1,660.62 - 1,734.94

Haleon Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Haleon Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Haleon's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Haleon Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Haleon PLC (XTER:H6D0) » Definitions » Short-Term Debt
Comparable Companies
LSE:HIK LSE:HCM LSE:INDV LSE:APH LSE:AGY LSE:ANCR LSE:EAH LSE:STX AQSE:ANA LSE:PXS ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 XSWX:GALD NSE:DIVISLAB HKSE:03692 XSWX:SDZ XTAE:TEVA SHSE:688506
Traded in Other Exchanges
HLNCF:USA HLN:USA HLN:Mexico HLNl:UK HLN:UK
Address
The Heights, Building 5, First Floor, Surrey, Weybridge, GBR, KT13 0NY
Website
https://www.haleon.com
Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon's brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.

Haleon Headlines

No Headlines